Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADC TherapeuticsADCT -6.67%41 Gross Margin % is 82.66% as of Mar. 2026, which is 14% below its 10-year median of 95.89. GuruFocus rates ADCT with a GF Score™ of 41/100 and a GF Value™ of $2.09 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 941 Drug Manufacturers companies, ADC Therapeutics ranks better than 97.77% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ADC Therapeutics had a gross margin of 82.66% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ADC Therapeutics Gross Margin % Related Terms
ADC Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for ADC Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADCT vs GNLX, VXRT, COYA: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ADC Therapeutics (ADCT) has a Gross Margin % of 82.66% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on ADC Therapeutics and its competitors. This is 14% below median its historical median of 95.89. Over the past decade, ADC Therapeutics' Gross Margin % has ranged from 90.71 to 98.43. According to the industry distribution chart, ADC Therapeutics ranks #21 out of 941 companies in the Drug Manufacturers industry, placing it in the top 2.2%.
Is ADC Therapeutics' Gross Margin % too high?
ADC Therapeutics' current Gross Margin % of 82.66% is 14% below median its 10-year median of 95.89. Over the past 10 years, this metric has ranged from a low of 90.71 to a high of 98.43. The Drug Manufacturers industry median Gross Margin % is 48.54. ADC Therapeutics' value of 82.66% is 70.3% above this industry median. Based on the distribution chart, ADC Therapeutics ranks #21 out of 941 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ADC Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' Gross Margin % compare to GNLX and VXRT?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #21 out of 941 companies for Gross Margin %. This places ADC Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. ADC Therapeutics' value of 82.66% is 70.3% above this benchmark. Historically, ADC Therapeutics' own Gross Margin % has ranged from 90.71 to 98.43 over the past decade. While the company's 10-year median is 95.89 vs. the industry median of 48.54, ADC Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADC Therapeutics's current Gross Margin % of 82.66% is 70.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ADC Therapeutics and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADC Therapeutics's current Gross Margin % is 82.66%, which is 14% below median its own 10-year median of 95.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.09, compared to a current price of $1.26 — trading 39.7% below its estimated fair value. The current Gross Margin % is 82.66%, which is 14% below median its 10-year median of 95.89 and 70.3% above the Drug Manufacturers industry median of 48.54. ADC Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current Gross Margin % is 82.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.26 is trading 39.7% below its estimated GF Value™ of $2.09.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
Gross Margin %: 82.66% (14% below median its 10-year median of 95.89)
GF Value™: $2.09 vs. price of $1.26 (39.7% below fair value)
Industry Position: 70.3% above the Drug Manufacturers median (#21 of 941)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score
Get the complete analysis for ADCT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
